Everything the planner shows comes from our compound records, each with its source. It shows what studies found on half-life, suppression and bloodwork; it never gives a dose, a protocol, a recovery date or a testing date.
Pick one or more compounds to see each half-life and what it means for drug levels, what studies found on testosterone suppression, the blood markers the studies tracked and the drugs researched for restoring testosterone.
How the planner works
- Drug levels. For each compound it takes the half-life in our record, with the group and route it was measured in, and multiplies it by five. Half of what is in the body is cleared every half-life, so after five half-lives about 3% is left (StatPearls). This is an illustration of concentration decay, not a personal calculation. If any selected compound has no human half-life, the planner gives no figure for the whole selection and names the compound that is missing.
- Suppression. It shows our 0–3 suppression score (0 = none found, 3 = marked), whether it rests on human or animal data, and a one-line summary of the studies, with a link to the source. “Not measured” means there are no data, which is not the same as no suppression.
- Cycle length check. If the weeks you enter are longer than any human study of a compound in our database, it says so. Many cycles described online are longer than anything that has been studied.
- Bloodwork. It lists every marker the studies of your compounds tracked, combined.
- Drugs researched for restoring testosterone. It always lists enclomiphene, clomiphene and tamoxifen with what the evidence says about each, whatever you select. None has been tested after SARM use.
- Shop listings. After the result, a separate section headed “Where to buy (affiliate links)” shows partner-shop listings. It is the same for every selection and is not derived from the result.
You can share or bookmark a result: the address keeps your selection (for example LGD-4033 + MK-677 for 8 weeks).
Clearance times in our records
| Compound | Half-life | About 3% left after (5 half-lives, illustration) | Source |
|---|---|---|---|
| Ostarine | ~14–24 h | About 3–5 days | Phase 1 data (EMERALD protocol) |
| LGD-4033 | 24–36 h | About 5–8 days | Basaria 2013 |
| RAD-140 | ~45 h (measured in women) | About 9 days | Phase 1, 2022 |
| Enclomiphene | ~8–10 h | About 2 days | EMA 2018 |
| Anastrozole | ~50 h | About 10 days | label |
| Tamoxifen | ~5–7 days (metabolite ~14 days) | About 4–5 weeks (metabolite longer) | label |
| Clomiphene | No single value | Not established: the zuclomiphene part lingers for weeks | label |
| MK-677, cardarine | No verified human value in our records | Not established |
Each figure is an illustration of how drug levels fall, based on one study population and route. They are not drug-test detection windows, which can be far longer (detection data are on each fact sheet), and they say nothing about when hormones recover.
What the planner does not do
- It does not give doses or a PCT protocol. No PCT has been tested after SARMs, so there is no evidence-based protocol to give. The planner shows what was studied and lets the evidence speak.
- It does not know your body. Half-lives were measured in specific groups (RAD-140 in women with cancer, for example) and vary between people.
- It does not time bloodwork or recovery. Drug levels falling is not the same as hormones recovering (see below).
- It cannot check what is in your bottle. In a 2017 analysis of 44 products sold online as SARMs, only 52% contained a SARM and only 41% the labeled amount (Van Wagoner 2017).
- It is not medical advice. It summarizes published research.
Clearance is not recovery
A falling drug level and a recovering hormone system are different things. When a compound is mostly cleared, that does not show that your own testosterone, LH and FSH have recovered, that a blood test now reflects your own levels, or whether or when any treatment (PCT) is appropriate. The planner therefore gives no recovery date, no testing date and no PCT start date.
Studies measure recovery separately from drug levels. In the LGD-4033 trial in healthy young men, drug levels were measured during 21 days of dosing, and hormones were followed for five weeks after the last dose to see whether they returned to baseline (Basaria 2013). The HAARLEM study of steroid users tested hormones before the cycle, at its end, 3 months after it and one year after the start (Smit 2021). For diagnosing low testosterone, the Endocrine Society recommends a fasting morning total testosterone, repeated to confirm a low value (Bhasin 2018). Which markers studies used and how to read them: SARMs bloodwork. The evidence on PCT itself: SARMs PCT.
Other tools: Stack checker (overlapping risks of a stack) and Compare (two compounds side by side).